SHANGHAI, Oct. 14 /PRNewswire-Asia/ -- A delegation from the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (All-CABPA) visited Sundia in Shanghai's famous Zhangjiang Hi-Tech Park on October 12.
The delegation consists of 13 members from SAPA, CABS, SABPA, and CABA, the four major associations for Chinese-American professionals in biotechnology and pharmaceutical industries in the U.S. They were invited to visit Shanghai by Zhangjiang Hi-Tech Park and the Commission of Science and Technology of the Municipal Government of Shanghai. In addition to Shanghai, they will also visit Suzhou and Wuxi. The group is using this opportunity to gather up-to-date information about the development of Chinese pharmaceutical and biotech industries, as well as looking for collaborations opportunities.
In the morning of October 12, all delegates flied to Shanghai from New Jersey, Boston, San Francisco, and San Diego, U.S. During their half day visit to Sundia, Dr. Xiaochuan Wang, the Chairman and CEO of Sundia welcomed the delegation and gave them a review about the development of Chinese CRO industry and the growth of Sundia. In her presentation, she mentioned that Sundia and many other CRO companies in China are continuing to hire experienced biomedical scientists and managers at senior and middle levels from the U.S. The delegation also spent time visiting Sundia's R&D facilities and meeting Sundia's scientists to hear their stories about conducting biomedical research in China.
Mr. Lanzhong Wang, General Manager of Zhangjiang Biotech-Pharmaceutical Base hosted the delegation in the afternoon. The Base is a part of the famous Zhangjiang Hi-Tech Park with focus on biotech and pharmaceutical sectors. He presented to the delegation the Base's history and current status, especially many incentive policies and practices to attract investment for startup high-tech companies in the park. During the visit, the delegation had a tour in Zhangjiang Hi-Tech Park Exhibition Center, which gave the guests a overall review of the Park's achievement and the investment environment.
After the visit, Dr. Junjun Wu, the delegation leader, said that they were deeply impressed with efforts that the government has made for the development of biopharmaceutical industry. The visit helped the guests to get a better understanding about the favorite policies in the Park to support innovation and talents, and how to run biomedical business and conducting biomedical research in Zhangjiang. Some guests expressed their wishes to cooperate with Zhangjiang Park in the future.
About Sundia MediTech
Sundia MediTech Company is a leading integrated pharmaceutical contract research organization (CRO) based in Shanghai, China. It was founded in Shanghai in 2004 by a group of U.S. pharmaceutical industry veterans to provide R&D outsourcing services to biotech and pharmaceutical companies worldwide, ranging from chemical services, medicinal chemistry, biological services, new technology platforms, and pharmaceutical development services.
Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (ALL-CABPA) was formed in 2008 including the Chinese American organizations in the biotechnology and pharmaceutical field: namely, the Chinese Biopharmaceutical Association (CBA), headquartered in Washington DC; the Chinese-American Biopharmaceutical Society (CABS), headquartered in San Francisco, CA; the Sino-American Biomedical and Pharmaceutical Professionals Association (SABPA), headquartered in San Diego, CA; and the Chinese-American Biomedical Association (CABA), headquartered in Boston, MA.
SOURCE Sundia MediTech Company
CONTACT: Li Zhao of Sundia, +86-21-51098642x167, or email@example.com